Abstract: Background and Objectives. Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions. Materials and Methods. During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded. Results. Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion-dependent adverse reactions in plasma group. Conclusion. Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.
BACKGROUND AND OBJECTIVES
Bleeding in a number of acute and chronic conditions that require medical and surgical treatment may be prevented and treated with platelet transfusions [1] . Prophylactic platelet concentrate (PC) transfusions in patients with severe thrombocytopenia have increased over the last years due to more frequent and more intensive radiations and chemotherapy treatments. PC may be obtained from whole blood collected into a multiple plastic bag set. The procedures for the preparation of PC from whole blood donations are the buffycoat (BC) and the platelet-rich plasma (PRP) methods. The former one is performed in Europe and the latter in North America and in several European countries. PCs obtained from BC may be diluted in autologous plasma or in a platelet additive solution (PAS). The use of a synthetic medium reduces the plasma content in every PC and therefore may reduce plasma-related adverse reactions. We have performed a prospective clinical trial trying to assess the relationship between PAS PCs, adverse reactions and their clinical effectiveness.
MATERIALS AND METHODS

PCs Preparation
PCs were prepared from pooled whole-blood-derived BCs. Units of whole blood (450±50 mL) were collected from volunteer donors in triple-bag bottom-and-top systems (Baxter. La Châtre, France) containing 63 mL of CPD and stored at 22ºC. Within 20 hours after collecting, the unit of whole blood was separated into its components by high-speed *Address correspondence to this author at the Centro de Transfusión de la Comunidad Valenciana, Avda del Cid 65, 46014 Valencia, Spain; Tel: 34963868143; Fax: 34963502469; E-mail: larrea_lui@gva.es centrifugation in an Heraeus centrifuge (6000, 8000 and 8500) and placed in an automated extractor system (Optipress II, Baxter) for the collection of red blood cells (RBC) and plasma, leaving the BC (volume, 54±2 mL;Hct,52±3%) in the collection bag [2, 3] . To obtain PCs following the Council of Europe guidelines [4] , 5 iso-group Buffy-coats were pooled diluted with either 300 mL of plasma or 300 mL of PAS-2 (T-Sol, Baxter, Lessines, Belgium) and centrifuge at low speed [5, 6] . The resulting ratio of plasma to PAS-2 in the storage medium was approximately 3:7. This ratio was calculated from the content of plasma in the BC units and the amount of PAS-2 added. The platelet-rich supernatant was collected in a 1.3-L plastic container (PL-2410, Baxter, Healthcare, Deerfield, IL) by placing the pool in an extrusion clamp. Platelet pools were stored at 22 ±2ºC on a flatbed shaker.
Depending on the time of storage, Eriksson et al. [7] divided PCs in fresh (one or two days) and stored (more than two days), we adopted this classification with slight changes; before transfusion PCs transfused the first 3 days of storage were considered fresh, while PCs transfused on day 4 or 5 were considered stored. PCs were analyzed for platelet count at each centre pre and post filtration with an automatic counter (Sysmex K800) and WBC count by means of a cytometer (FACS Calibur-Becton-Dickinson).
Platelet Transfusion Protocol
During six months, following ethical approval and after informed consent was obtained, 51 patients over the age of 18, treated with intensive chemotherapy for hematological malignancies or with stem cell transplantation as intensification treatment for solid tumors, were called for this prospective study. Patients were excluded if they had been multitransfused (more than nine units of blood derivatives previ-ously received) before or if a severe hemorrhage existed. Reason for excluding multitransfused patients was in order to avoid bias on platelet recovery and on adverse reactions analysis. Eligible patients were randomly assigned to receive, on a prophylactic basis, PCs suspended in either plasma or PAS-2. Ninety-nine platelet concentrates (43 with plasma and 56 with PAS-2) were transfused. The transfusion trigger for platelets was 20x10 9 or less. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded. CCI values by the following equation:
Number of platelets transfused x 10 11 .
The study was performed at the University Hospital La Fe and at the University Clinic Hospital, Valencia, Spain. Medication, blood pressure and temperature before and after each transfusion were recorded. The following information was also recorded: age, sex, number of previous transfused units, diagnosis, reason for admission, pre and post filtration PCs volume, platelet count and leukocyte number, and pre filtration pH value at 37º and 22º centigrade of platelet concentrates.
Platelet filtration was made at bedside with PXL3KLE PALL filter. Transfusion-dependent adverse reactions were defined according to three categories: Febrile non-hemolytic reactions (FNHTR), allergic transfusion reactions and other reactions. FNHTR were defined as an increase in body temperature (>1ºC) with or without chills during and up to 4 hours after the transfusion that could not be attributed to the patient's condition, and was documented by the clinical staff. Allergic transfusion reactions were characterized as the development of urticaria or rashes with pruritus during and up to 4 hours after the transfusion. Remaining adverse effects related to transfusion were categorized as "other reactions".
A comparison was made of CCI, platelet count increment, hemorrhage after transfusion, transfusion related reactions and changes of clinical parameters such as temperature, cardiac rate, blood pressure.
Statistical Analysis
For statistical analysis, Student's t test, Mann-Whitney's U and Pearson 2 test were applied with the use of a software program. A probability of p<0.05 was used to reject the null hypothesis. Table 1 shows patient's characteristics in the studied population. Pre and postfiltration platelet number, leukocyte number and volume in plasma group PCs were significantly higher than in PAS-2 group ( Table 2) . Platelet count, platelet increment and CCIs one after transfusion were similar in both groups ( Table 2) . We also compared post filtration leukocyte count in patients with and without reactions, but we failed to show any significant difference. Table 3 shows the CCI data found after transfusion of fresh and stored PCs. Eighteen plasma PC transfusions and 41 PAS-2 PC transfusions were given the first 3 days of storage, and they were considered fresh. The remaining PCs were transfused on day 4 or 5, and each being considered stored. In each platelet group 1-hour CCIs found after the transfusion of fresh and stored PCs were similar. In an effort to establish a difference among groups, we estimated the efficiency of transfusion by determining the percentage of platelet transfusions above an arbitrary CCI threshold. More than 75% of both plasma (88.8%) and PAS-2 (73.4%) transfusions were above the CCI threshold of 7.5. When the CCI threshold was set at 15, 27% of plasma PCs transfusions and 39.2% of PAS-2 PC transfusions were above that threshold. We were not able to collect data about adverse reactions in three transfusion episodes from PAS-2 PC group. When we analyzed incidence of transfusion reactions we observed that in plasma group, and in PAS-2 group eight out of 43 (18.6%) transfusions and two out of 53 (3.8%) transfusions had reactions respectively, the difference was significant. Distribution of adverse reactions depending on type may be seen in Table 4 . Taking only the fresh transfusions the difference of appearance of reactions between plasma and PAS-2 groups kept on being significative but this difference disappeared if we analyzed only the stored PCs ( Table 4) .
RESULTS
There were scarce and mild hemorrhagic episodes after PCs transfusion without differences inter-groups (p>0.05); 6/43 (14%) in plasma group and 3/53 (5.7%) in PAS-2 group.
No statistic relationship was found between number of previous transfusions, temperature, blood pressure and concomitant drugs with efficiency of transfusion, adverse reactions and hemorrhage.
DISCUSSION
The need for source material for plasma products and improving the quality of red cells for transfusion selected the methods for blood components in the 1970s and 1980s. The possibility to make PC from buffy-coats instead of from platelet-rich plasma has proven to be effective in increasing the national supply of plasma components and has become accepted as the normal standard procedure in the first half of the 1990s. Using this methodology we can obtain PCs with less leukocytes and spare plasma obtaining per whole blood unit more volume than with the PRP method. This saving could be increased by using PAS instead of plasma as a storage medium for PCs. After the decision to adopt PAS-2 methodology had been made we should guarantee that these PAS-2-PCs should be optimal not only taking into account in vitro results but also its clinical efficiency. PAS displays several advantages over the use of plasma for preparation of PCs. These benefits include reduction of the number of allergic reactions [8, 9] , while more plasma becomes available for fractioning. Due to the absence of anti-A and anti-B, ABO-incompatible transfusions are better tolerated [10] , life-threatening anaphylaxis or febrile nonhemolytic transfusion reactions after transfusion of PCs is a serious clinical problem caused by the sensitizing of recipients to plasma components, such as cytokines [11] . The use of an additive solution as the major component of the platelet storage medium was first described by Rock et al. [12] . The preparation and storage of PCs in a platelet additive solution (PAS-2) have been shown to result in acceptable storage conditions [9] but require the carryover of substantial (30%) amounts of plasma for success. Platelet additive solutions can be used as a substitute for plasma in order to recover plasma for other purposes, to avoid transfusion of large volumes of plasma to patients, to improve storage conditions, and to make possible photochemical treatment for viral inactivation of PCs [13] . Platelets remain relatively unaltered and more stable in plasma in comparison to storage in PAS-2 [14] . Currently, several platelet additive solutions for longterm platelet storage have been introduced, storing platelets in additive solution containing magnesium and potassium (PASIIIM) improves the functionality of the platelets, as measured by glycolysis, Ph, morphology, ATP and CD62 expression [15] , and may allow a reduction of the amount of plasma required to be carried over to the final unit, facilitating some methods of viral inactivation and making available greater amounts of plasma for other needs [16] .
In order to evaluate the clinical efficiency of PCs, CCI is to be recommended for frequent use [17] . In a prospective study a comparison of the corrected post transfusion increment was made between fresh (1-2 days) and stored (3-5 days) preparations, fresh BC-PCs gave higher increments than stored BC-PCs [7] . A major concern related to the use of PAS-2-PCs could be lost of its therapeutic properties translated into an increase of bleeding episodes; in our study, use of PAS-2 resulted in good CCI in both groups and without differences in clinical effectiveness (measured by bleeding). PAS-2 group was associated with less transfusion related reactions, we think that this reduction in adverse reactions in PAS-2-PCs may be related with the presence of fewer leukocytes or less protein content in PAS-2 platelet concentrates. Even if to be expected from the pathophysiologic mechanism (leukocytes in the case of FNHTR and plasma proteins in the case of allergic reactions), differences might be accidental due to residual plasma and leukocyte count in PAS-2-PCs, though significantly less, might be enough to cause an undesirable reaction. When we compared post filtration leukocyte count in patients with and without reactions, we failed to show any significant difference; also we could not distinguish differences in adverse reaction subgroups and type of PC, these two facts could be easily explained by the small sample size.
Platelet activity studies are still needed (under basal conditions and after activation) after platelet transfusion in both groups. Since less transfusion-dependent reactions were observed in patients who obtained PCs diluted with PAS2 instead of plasma, which could not be linked to differences in platelet counts, the study of platelet activity in both groups would greatly improve the quality of this study.
Taking into account that PAS-2-PC results in haemostatic effect of equal quality to plasma-PC and in less transfusion associated morbidity, it seems advisable to elaborate PCs using synthetic additive solutions. 
